|
gptkbp:instanceOf
|
gptkb:monoclonal_antibody
immunosuppressant
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvalYear
|
2017
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L04AA36
|
|
gptkbp:brand
|
gptkb:Ocrevus
|
|
gptkbp:CASNumber
|
923409-53-6
|
|
gptkbp:contraindication
|
active hepatitis B infection
|
|
gptkbp:developedBy
|
gptkb:Genentech
gptkb:Roche
|
|
gptkbp:halfLife
|
26 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ocrelizumab
|
|
gptkbp:immunoglobulinType
|
gptkb:IgG1
|
|
gptkbp:indication
|
primary progressive multiple sclerosis
relapsing multiple sclerosis
|
|
gptkbp:KEGGID
|
D10572
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
gptkb:CD20_antigen
humanized monoclonal antibody
|
|
gptkbp:mechanismOfAction
|
B cell depletion
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:PubChem_CID
|
none
CHEMBL2108707
DB11912
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
infections
infusion reactions
malignancy risk
|
|
gptkbp:target
|
gptkb:CD20
|
|
gptkbp:UNII
|
7LJ0877QWK
|
|
gptkbp:usedFor
|
multiple sclerosis
|
|
gptkbp:bfsParent
|
gptkb:primary_progressive_MS
|
|
gptkbp:bfsLayer
|
6
|